Welcome to our dedicated page for Innoviva news (Ticker: INVA), a resource for investors and traders seeking the latest updates and insights on Innoviva stock.
Innoviva, Inc. (INVA) delivers transformative healthcare solutions through strategic management of biopharmaceutical assets and royalty portfolios. This news hub provides investors with essential updates on the company's respiratory therapy developments, partnership milestones, and financial performance.
Access authoritative reporting on INVA's operational achievements including critical care innovations, licensing agreements, and portfolio expansions. Our curated news collection features earnings announcements, regulatory updates, and strategic collaborations that shape the company's unique position in biopharmaceutical markets.
Key coverage areas: quarterly financial results, therapeutic asset developments, partnership expansions with global pharmaceutical leaders, and analysis of royalty revenue trends. Stay informed about INVA's progress in infectious disease research and respiratory treatment advancements.
Bookmark this page for streamlined access to verified Innoviva updates. Monitor the company's strategic navigation of healthcare markets through timely reports on asset performance and industry leadership.
Innoviva (NASDAQ: INVA) reported strong Q2 2024 financial results, showcasing growth across multiple fronts. Key highlights include:
- GSK royalties of $67.2 million, up from $65.7 million in Q2 2023
- Net product sales of $21.7 million, a 38% year-over-year increase
- License revenue of $14.5 million, including an $8 million milestone payment for XACDURO® approval in China
- Net loss of $34.7 million, primarily due to unfavorable changes in investment fair values
- Completed $100 million share repurchase program
The company's core products, XACDURO® and XERAVA®, received recognition in important treatment guidelines. Innoviva remains focused on enhancing shareholder value through capital allocation and operational excellence.
Innoviva (Nasdaq: INVA), a diversified holding company with a core royalties portfolio and a strong presence in critical care and infectious disease through Innoviva Specialty Therapeutics (IST), announced that its CEO, Pavel Raifeld, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. The event will take place in Miami, FL on June 10, 2024, at 1:20 p.m. Eastern Time. The session will be available via live webcast on the company's Investor Relations webpage and can be replayed for 90 days.
Innoviva, Inc. (NASDAQ: INVA) reported strong first quarter financial results with $61.9 million in GSK royalties, $19.1 million in net product revenues, and a successful pipeline. The company highlighted positive Phase 3 zoliflodacin clinical trial results and key appointments.
Innoviva, Inc. (NASDAQ: INVA) will participate in the BofA Securities Health Care Conference. The company, a holding firm with a core royalties portfolio and a strong presence in critical care and infectious disease treatment, will have its CEO, Pavel Raifeld, present at the conference on May 15, 2024. Interested parties can access a live webcast of the event on the company's Investor Relations website.
FAQ
What is the current stock price of Innoviva (INVA)?
What is the market cap of Innoviva (INVA)?
